Zydus announces Phase I trials of ZYIL1 for IBD, ARDS and multiple sclerosis
Studies have demonstrated that ZYIL1 can selectively supress inflammation caused by the NLRP3 inflammasome
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.